Nature Search

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

Cibisatamab is a T-cell bispecific antibody targeting the carcinoembryonic antigen (CEA) on tumor cells and CD3 epsilon chain on T cells. Here the authors report the results of two clinical trials of cibisatamab as monotherapy (NCT02324257) and in combination with atezolizumab (anti-PD-L1; NCT02650713) in patients with CEA-positive solid tumors.

Neil H. Segal
Ignacio Melero
Guillem Argilés
ResearchOpen Access15 May 2024
Nature Communications

Volume: 15, P: 1-14
A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

Some cancer patients first present with metastases where the location of the primary is unidentified; these are difficult to treat. In this study, using machine learning, the authors develop a method to determine the tissue of origin of a cancer based on whole sequencing data.

Wei Jiao
Gurnit Atwal
Christian von Mering
ResearchOpen Access05 Feb 2020
Nature Communications

Volume: 11, P: 1-12
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial

In this phase 1 trial, patients with locally advanced or metastatic solid tumors were treated with the individualized mRNA neoantigen-specific immunotherapy (iNeST) autogene cevumeran alone or in combination with the anti-PD-L1 agent atezolizumab, showing long-lasting neoantigen-specific immune responses and preliminary clinical activity, supporting further development of this therapeutic approach.

Juanita Lopez
Thomas Powles
D. Ross Camidge
ResearchOpen Access06 Jan 2025
Nature Medicine

Volume: 31, P: 152-164
The mutational footprints of cancer therapies

Analysis of whole-genome sequences from more than 3,500 metastatic tumors identifies mutational signatures associated with different chemotherapies and provides estimates of the relative contribution of different treatments to tumor mutational burden.

Oriol Pich
Ferran Muiños
Nuria Lopez-Bigas
Research18 Nov 2019
Nature Genetics

Volume: 51, P: 1732-1740
Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors

Michiel C. Verboom
Jacqueline S. L. Kloth
Henk-Jan Guchelaar
Research04 Feb 2019
The Pharmacogenomics Journal

Volume: 19, P: 473-479
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial

Exploratory ctDNA analyses from the phase 3 INTRIGUE trial indicate that ripretinib may provide benefits in patients with advanced gastrointestinal stromal tumors with KIT exon 11 + 17/18 mutations

Michael C. Heinrich
Robin L. Jones
Sebastian Bauer
ResearchOpen Access05 Jan 2024
Nature Medicine

Volume: 30, P: 498-506
Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features

Molecular landscapes of metastatic colorectal cancers (mCRC) have often been restricted to coding regions or low numbers of patients. Here the authors present a whole-genome landscape of 429 mCRC patients, revealing the mutational impact of prior therapies and potential actionable targets.

Pauline A. J. Mendelaar
Marcel Smid
Saskia M. Wilting
ResearchOpen Access25 Jan 2021
Nature Communications

Volume: 12, P: 1-11
Author Correction: Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features

Pauline A. J. Mendelaar
Marcel Smid
Saskia M. Wilting
Amendments and CorrectionsOpen Access26 May 2021
Nature Communications

Volume: 12, P: 1
The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact

Detecting genomic abnormalities in metastatic castration-resistant prostate cancer (mCRPC) may impact clinical treatment. Here, the authors present whole-genome sequencing of metastatic biopsies from 197 mCRPC patients, highlighting the landscape of microsatellite stability, homologous repair deficiency, and other genomic subgroups.

Lisanne F. van Dessel
Job van Riet
Martijn P. Lolkema
ResearchOpen Access20 Nov 2019
Nature Communications

Volume: 10, P: 1-13
The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies

Whole-genome sequencing of metastatic biopsies from 442 patients with breast cancer provides insights into metastatic disease, including associations of genomic features with prior treatments and identification of therapeutic vulnerabilities.

Lindsay Angus
Marcel Smid
John W. M. Martens
Research30 Sept 2019
Nature Genetics

Volume: 51, P: 1450-1458
Pervasive chromosomal instability and karyotype order in tumour evolution

Chromosomal instability enables the continuous selection of somatic copy number alterations, which are established as ordered events that often occur in parallel, throughout tumour evolution and metastasis.

Thomas B. K. Watkins
Emilia L. Lim
Charles Swanton
Research02 Sept 2020
Nature

Volume: 587, P: 126-132
Pan-cancer whole-genome analyses of metastatic solid tumours

The mutational landscape of metastatic cancer genomes is analysed in a large-scale, pan-cancer study of metastatic solid tumours that includes whole-genome sequencing of 2,520 tumour–normal tissue pairs.

Peter Priestley
Jonathan Baber
Edwin Cuppen
ResearchOpen Access23 Oct 2019
Nature

Volume: 575, P: 210-216
Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

Wei Jiao
Gurnit Atwal
Christian von Mering
Amendments and CorrectionsOpen Access08 Dec 2022
Nature Communications

Volume: 13, P: 1
Unsolicited findings of next-generation sequencing for tumor analysis within a Dutch consortium: clinical daily practice reconsidered

Rhodé M Bijlsma
Annelien L Bredenoord
Neeltje Steeghs
Research13 Apr 2016
European Journal of Human Genetics

Volume: 24, P: 1496-1500
Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial

Desmond Yip
John Zalcberg
Heikki Joensuu
ResearchOpen Access25 Mar 2025
British Journal of Cancer

Volume: 132, P: 897-904
Feasibility and efficacy of therapeutic drug monitoring of abiraterone in metastatic castration resistant prostate cancer patients

Maud B. A. van der Kleij
Marinda Meertens
Maud B. A. van der Kleij
ResearchOpen Access11 Feb 2025
British Journal of Cancer

Volume: 132, P: 635-642
Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology – an analysis of the closed cohorts of a multicentre prospective study

Maud B. A. van der Kleij
Niels A. D. Guchelaar
Neeltje Steeghs
ResearchOpen Access06 Jul 2024
British Journal of Cancer

Volume: 131, P: 843-851
First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours

Debbie Robbrecht
Christiane Jungels
Ahmad Awada
Research13 Dec 2021
British Journal of Cancer

Volume: 126, P: 1010-1017
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

Robin M. J. M. van Geel
Emilie M. J. van Brummelen
Jan H. M. Schellens
ResearchOpen Access09 Mar 2020
British Journal of Cancer

Volume: 122, P: 1166-1174
Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer

Ruud van der Noll
Serena Marchetti
Jan H M Schellens
ResearchOpen Access16 Jul 2015
British Journal of Cancer

Volume: 113, P: 396-402

Search

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial

The mutational footprints of cancer therapies

Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial

Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features

Author Correction: Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact

The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies

Pervasive chromosomal instability and karyotype order in tumour evolution

Pan-cancer whole-genome analyses of metastatic solid tumours

Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

Unsolicited findings of next-generation sequencing for tumor analysis within a Dutch consortium: clinical daily practice reconsidered

Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial

Feasibility and efficacy of therapeutic drug monitoring of abiraterone in metastatic castration resistant prostate cancer patients

Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology – an analysis of the closed cohorts of a multicentre prospective study

First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer

Search

Quick links

Search

Filter By:

Search

Quick links